Takeda Historical Financial Ratios

TAK Stock

USD 13.38 0.05 0.38%

Takeda Pharmaceutical is promptly reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 4.9 K, Free Cash Flow Yield of 0.0316, Invested Capital of 0.0 or Operating Cash Flow Per Share of 430 will help investors to properly organize and evaluate Takeda Pharmaceutical financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Takeda Financial Ratios Analysis

Takeda PharmaceuticalFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Takeda Pharmaceutical investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Takeda financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Takeda Pharmaceutical history.

Takeda Pharmaceutical Financial Ratios Chart

At this time, Takeda Pharmaceutical's Capex To Depreciation is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 135.69 this year, although the value of Stock Based Compensation To Revenue will most likely fall to 0.01.

Price To Sales Ratio Dividend Yield Ptb Ratio Days Sales Outstanding Free Cash Flow Yield Cash Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Takeda Pharmaceutical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Takeda Pharmaceutical sales, a figure that is much harder to manipulate than other Takeda Pharmaceutical Co multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Takeda Pharmaceutical Co dividend as a percentage of Takeda Pharmaceutical stock price. Takeda Pharmaceutical dividend yield is a measure of Takeda Pharmaceutical stock productivity, which can be interpreted as interest rate earned on an Takeda Pharmaceutical investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most ratios from Takeda Pharmaceutical's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2024 (projected)
Dividend Yield	0.0519	0.0414	0.0463
Price To Sales Ratio	1.53	1.68	1.45

Dividend Yield Price To Sales Ratio

Takeda Pharmaceutical fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.83	0.95	0.5	-0.74	-0.49	-0.66	0.36	0.95	0.95	-0.46	0.33	0.77	-0.35	-0.42	0.03	-0.53	0.01	0.29	0.65	-0.42	-0.02	0.34	-0.02	-0.45	0.42
Dividend Yield	-0.83		-0.87	-0.52	0.83	0.72	0.87	-0.14	-0.87	-0.88	0.69	-0.13	-0.56	0.47	0.27	-0.11	0.52	0.18	-0.4	-0.43	0.57	-0.15	-0.26	0.0	0.69	-0.25
Ptb Ratio	0.95	-0.87		0.39	-0.85	-0.54	-0.73	0.26	1.0	0.89	-0.52	0.24	0.81	-0.43	-0.56	0.2	-0.55	-0.13	0.4	0.55	-0.44	0.11	0.24	-0.17	-0.51	0.37
Days Sales Outstanding	0.5	-0.52	0.39		-0.32	-0.27	-0.48	0.02	0.39	0.68	-0.25	0.04	0.17	-0.29	0.28	-0.13	-0.48	0.26	0.1	0.19	-0.14	-0.09	0.26	0.21	-0.16	0.06
Book Value Per Share	-0.74	0.83	-0.85	-0.32		0.43	0.76	0.19	-0.85	-0.73	0.43	0.02	-0.54	0.49	0.44	-0.19	0.74	0.1	-0.41	-0.47	0.32	-0.1	-0.12	0.13	0.45	-0.29
Free Cash Flow Yield	-0.49	0.72	-0.54	-0.27	0.43		0.85	-0.31	-0.54	-0.52	0.99	-0.03	-0.46	0.52	0.3	-0.24	0.03	0.51	-0.44	-0.15	0.23	-0.4	-0.17	0.15	0.45	0.07
Operating Cash Flow Per Share	-0.66	0.87	-0.73	-0.48	0.76	0.85		0.05	-0.73	-0.71	0.86	0.06	-0.51	0.7	0.32	-0.22	0.55	0.3	-0.54	-0.31	0.21	-0.35	-0.14	0.14	0.45	0.0
Capex To Depreciation	0.36	-0.14	0.26	0.02	0.19	-0.31	0.05		0.26	0.27	-0.25	0.63	0.5	0.3	-0.25	-0.13	0.54	-0.34	-0.11	0.29	-0.2	-0.06	0.18	0.12	-0.11	0.39
Pb Ratio	0.95	-0.87	1.0	0.39	-0.85	-0.54	-0.73	0.26		0.89	-0.52	0.24	0.81	-0.43	-0.56	0.2	-0.55	-0.13	0.4	0.55	-0.44	0.11	0.24	-0.17	-0.51	0.37
Ev To Sales	0.95	-0.88	0.89	0.68	-0.73	-0.52	-0.71	0.27	0.89		-0.49	0.22	0.6	-0.41	-0.18	0.02	-0.56	0.03	0.27	0.53	-0.41	-0.04	0.34	0.05	-0.44	0.35
Free Cash Flow Per Share	-0.46	0.69	-0.52	-0.25	0.43	0.99	0.86	-0.25	-0.52	-0.49		0.03	-0.44	0.58	0.3	-0.26	0.07	0.52	-0.49	-0.14	0.16	-0.46	-0.12	0.19	0.4	0.13
Roic	0.33	-0.13	0.24	0.04	0.02	-0.03	0.06	0.63	0.24	0.22	0.03		0.54	0.6	-0.33	-0.23	0.09	-0.23	-0.04	0.49	-0.15	-0.09	-0.1	0.27	-0.16	0.85
Inventory Turnover	0.77	-0.56	0.81	0.17	-0.54	-0.46	-0.51	0.5	0.81	0.6	-0.44	0.54		-0.21	-0.84	0.21	-0.29	-0.34	0.23	0.62	-0.25	0.05	0.24	-0.2	-0.31	0.44
Net Income Per Share	-0.35	0.47	-0.43	-0.29	0.49	0.52	0.7	0.3	-0.43	-0.41	0.58	0.6	-0.21		0.17	-0.32	0.46	0.15	-0.28	-0.06	-0.01	-0.17	-0.3	0.32	0.09	0.58
Days Of Inventory On Hand	-0.42	0.27	-0.56	0.28	0.44	0.3	0.32	-0.25	-0.56	-0.18	0.3	-0.33	-0.84	0.17		-0.31	0.15	0.37	-0.22	-0.36	0.13	-0.13	-0.11	0.33	0.21	-0.25
Payables Turnover	0.03	-0.11	0.2	-0.13	-0.19	-0.24	-0.22	-0.13	0.2	0.02	-0.26	-0.23	0.21	-0.32	-0.31		-0.03	-0.35	0.18	-0.13	0.03	0.2	0.01	-0.91	-0.05	-0.19
Capex To Revenue	-0.53	0.52	-0.55	-0.48	0.74	0.03	0.55	0.54	-0.55	-0.56	0.07	0.09	-0.29	0.46	0.15	-0.03		-0.29	-0.33	-0.42	0.08	-0.02	-0.02	0.03	0.18	-0.17
Cash Per Share	0.01	0.18	-0.13	0.26	0.1	0.51	0.3	-0.34	-0.13	0.03	0.52	-0.23	-0.34	0.15	0.37	-0.35	-0.29		-0.06	-0.11	-0.1	-0.18	0.13	0.2	0.03	-0.08
Pocfratio	0.29	-0.4	0.4	0.1	-0.41	-0.44	-0.54	-0.11	0.4	0.27	-0.49	-0.04	0.23	-0.28	-0.22	0.18	-0.33	-0.06		0.0	-0.06	0.93	-0.62	-0.26	-0.33	0.01
Interest Coverage	0.65	-0.43	0.55	0.19	-0.47	-0.15	-0.31	0.29	0.55	0.53	-0.14	0.49	0.62	-0.06	-0.36	-0.13	-0.42	-0.11	0.0		-0.2	-0.23	0.15	0.06	-0.22	0.52
Payout Ratio	-0.42	0.57	-0.44	-0.14	0.32	0.23	0.21	-0.2	-0.44	-0.41	0.16	-0.15	-0.25	-0.01	0.13	0.03	0.08	-0.1	-0.06	-0.2		0.06	-0.33	-0.08	0.93	-0.1
Capex To Operating Cash Flow	-0.02	-0.15	0.11	-0.09	-0.1	-0.4	-0.35	-0.06	0.11	-0.04	-0.46	-0.09	0.05	-0.17	-0.13	0.2	-0.02	-0.18	0.93	-0.23	0.06		-0.71	-0.27	-0.22	-0.14
Pfcf Ratio	0.34	-0.26	0.24	0.26	-0.12	-0.17	-0.14	0.18	0.24	0.34	-0.12	-0.1	0.24	-0.3	-0.11	0.01	-0.02	0.13	-0.62	0.15	-0.33	-0.71		0.06	-0.15	-0.16
Days Payables Outstanding	-0.02	0.0	-0.17	0.21	0.13	0.15	0.14	0.12	-0.17	0.05	0.19	0.27	-0.2	0.32	0.33	-0.91	0.03	0.2	-0.26	0.06	-0.08	-0.27	0.06		0.0	0.24
Income Quality	-0.45	0.69	-0.51	-0.16	0.45	0.45	0.45	-0.11	-0.51	-0.44	0.4	-0.16	-0.31	0.09	0.21	-0.05	0.18	0.03	-0.33	-0.22	0.93	-0.22	-0.15	0.0		-0.11
Roe	0.42	-0.25	0.37	0.06	-0.29	0.07	0.0	0.39	0.37	0.35	0.13	0.85	0.44	0.58	-0.25	-0.19	-0.17	-0.08	0.01	0.52	-0.1	-0.14	-0.16	0.24	-0.11

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	3.42	1.57	1.95	1.53	1.68	1.45
Dividend Yield	0.0549	0.0455	0.0519	0.0414	0.0441	0.0463
Ptb Ratio	1.09	1.2	0.96	1.06	0.89	0.85
Days Sales Outstanding	87.05	92.76	74.08	61.78	59.72	95.78
Book Value Per Share	3.0K	3.3K	3.6K	4.1K	4.6K	4.9K
Free Cash Flow Yield	0.0878	0.12	0.17	0.0509	0.0245	0.0316
Operating Cash Flow Per Share	430.1	647.2	718.33	629.69	409.29	429.76
Stock Based Compensation To Revenue	0.008848	0.0118	0.0122	0.0151	0.0168	0.00912
Pb Ratio	1.09	1.2	0.96	1.06	0.89	0.85
Ev To Sales	2.92	3.09	2.51	2.63	2.55	2.43
Free Cash Flow Per Share	290.29	495.81	599.34	221.33	102.01	135.69
Roic	(0.007456)	0.0533	0.035	0.0386	0.0483	0.0778
Inventory Turnover	1.43	1.32	1.3	1.26	1.72	2.46
Net Income Per Share	28.41	240.72	147.14	204.29	92.09	138.75
Days Of Inventory On Hand	254.42	276.74	281.35	289.42	212.43	151.22
Payables Turnover	5.15	4.28	3.74	4.05	6.5	3.73
Capex To Revenue	0.0661	0.0739	0.0521	0.16	0.11	0.12
Cash Per Share	419.62	642.01	559.64	356.81	302.27	287.16
Pocfratio	7.69	6.16	4.87	6.91	10.16	9.65
Interest Coverage	0.61	2.05	2.77	2.89	1.39	1.32
Payout Ratio	1.31	6.39	0.75	0.88	1.99	2.09
Capex To Operating Cash Flow	0.33	0.23	0.17	0.65	0.75	0.79
Pfcf Ratio	11.4	8.04	5.84	19.65	40.77	37.08
Days Payables Outstanding	70.88	85.2	97.59	90.2	56.18	105.74
Income Quality	15.12	2.69	4.88	3.08	4.44	4.67
Roe	0.009366	0.0727	0.0405	0.0499	0.0198	0.0188
Ev To Operating Cash Flow	14.34	9.79	7.98	10.85	17.01	30.49
Pe Ratio	116.44	16.55	23.77	21.29	45.16	33.62
Return On Tangible Assets	0.00954	0.0757	0.0465	0.0647	0.0266	0.0252
Ev To Free Cash Flow	21.25	12.77	9.57	30.86	68.25	36.59
Earnings Yield	0.008588	0.0604	0.0421	0.047	0.0221	0.0299
Net Debt To E B I T D A	5.06	3.73	2.95	3.25	5.01	5.27
Current Ratio	1.21	1.13	1.53	0.97	1.11	1.05
Tangible Book Value Per Share	(2.2K)	(1.8K)	(1.6K)	(1.7K)	(1.5K)	(1.5K)
Receivables Turnover	4.19	3.93	4.93	5.91	6.11	3.47
Graham Number	1.4K	4.2K	3.5K	4.3K	3.1K	1.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.049

Dividend Share

192

Earnings Share

0.59

Revenue Per Share

1.4 K

Quarterly Revenue Growth

0.127

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Takeda Historical Financial Ratios

About Takeda Financial Ratios Analysis

Takeda Pharmaceutical Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ptb Ratio

Free Cash Flow Yield

Takeda Pharmaceutical fundamentals Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 0.99	Free Cash Flow Yield
Ptb Ratio	+ 0.95	Price To Sales Ratio
Pb Ratio	+ 0.95	Price To Sales Ratio
Ev To Sales	+ 0.95	Price To Sales Ratio
Capex To Operating Cash Flow	+ 0.93	Pocfratio

Days Payables Outstanding	- 0.91	Payables Turnover
Ev To Sales	- 0.88	Dividend Yield
Pb Ratio	- 0.87	Dividend Yield
Ptb Ratio	- 0.87	Dividend Yield
Pb Ratio	- 0.85	Book Value Per Share
Book Value Per Share	- 0.85	Ptb Ratio